[HTML][HTML] Fast evolution of SARS-CoV-2 BA. 2.86 to JN. 1 under heavy immune pressure

S Yang, Y Yu, Y Xu, F Jian, W Song… - The Lancet Infectious …, 2024 - thelancet.com
The SARS-CoV-2 saltation variant BA. 2.86, which was quickly designated as a variant
under monitoring after its emergence, has garnered global attention. Although BA. 2.86 did …

SARS-CoV-2 BA. 2.86 enters lung cells and evades neutralizing antibodies with high efficiency

L Zhang, A Kempf, I Nehlmeier, A Cossmann, A Richter… - Cell, 2024 - cell.com
Summary BA. 2.86, a recently identified descendant of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) Omicron BA. 2 sublineage, contains∼ 35 mutations …

[HTML][HTML] A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long …

MI Prasanth, DL Wannigama, AM Reiersen… - Scientific Reports, 2024 - nature.com
Abstract There have been 774,075,242 cases of COVID-19 and 7,012,986 deaths worldwide
as of January 2024. In the early stages of the pandemic, there was an urgent need to reduce …

[HTML][HTML] Anticipating the future of the COVID-19 pandemic: insights into the emergence of SARS-CoV-2 variant JN. 1 and its projected impact on older adults

J Quarleri, MV Delpino, V Galvan - GeroScience, 2024 - Springer
The initial instance of a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
infection was observed in December 2019 in the city of Wuhan, China. Subsequently, the …

[HTML][HTML] Antigenicity assessment of SARS-CoV-2 saltation variant BA. 2.87. 1

S Yang, Y Yu, F Jian, A Yisimayi, W Song… - Emerging Microbes & …, 2024 - Taylor & Francis
The recent emergence of a SARS-CoV-2 saltation variant, BA. 2.87. 1, which features 65
spike mutations relative to BA. 2, has attracted worldwide attention. In this study, we …

[HTML][HTML] SARS-CoV-2 BA. 2.86 (“Pirola”): Is it Pi or Just Another Omicron Sublineage?

D Focosi, PG Spezia, F Maggi - Vaccines, 2023 - mdpi.com
Vaccines | Free Full-Text | SARS-CoV-2 BA.2.86 (“Pirola”): Is it Pi or Just Another
Omicron Sublineage? Next Article in Journal / Special Issue Analysing the In-Use Stability of …

[HTML][HTML] SARS-CoV-2 Omicron subvariant BA. 2.86: limited potential for global spread

X Wang, L Lu, S Jiang - Signal Transduction and Targeted Therapy, 2023 - nature.com
In recent studies published in Nature and Lancet Infectious Diseases, 1, 2 SARS-CoV-2
Omicron subvariant BA. 2.86 exhibited a substantial antigenic drift, enhanced receptor …

[HTML][HTML] Modeling vaccination strategies with limited early COVID-19 vaccine access in low-and middle-income countries: A case study of Thailand

S Anupong, T Chantanasaro, C Wilasang… - Infectious Disease …, 2023 - Elsevier
Low-and middle-income countries faced significant challenges in accessing COVID-19
vaccines during the early stages of the pandemic. In this study, we utilized an age-structured …

[HTML][HTML] Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a …

DL Wannigama, C Hurst, P Phattharapornjaroen… - …, 2024 - thelancet.com
Background Repurposed drugs with host-directed antiviral and immunomodulatory
properties have shown promise in the treatment of COVID-19, but few trials have studied …

[HTML][HTML] Evaluation of colorimetric RT-LAMP for screening of SARS-CoV-2 in untreated wastewater

J Akter, WJM Smith, M Gebrewold, I Kim… - Science of The Total …, 2024 - Elsevier
This study compared reverse transcription-loop-mediated isothermal amplification (RT-
LAMP) and three reverse transcription-quantitative polymerase chain reaction (RT-qPCR) …